July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Efficacy of Topical Ophthalmic Agent VBP-100 Against Multi-Drug Resistant Biofilms of Staphylococcus aureus,Klebsiella pneumoniae, Pseudomonas aeruginosa and Candida albicans.
Author Affiliations & Notes
  • Joseph Capriotti MD
    Veloce BioPharma LLC, Fort Lauderdale, Florida, United States
  • Jesse Pelletier MD FACS
    Veloce BioPharma LLC, Fort Lauderdale, Florida, United States
  • Kara Capriotti
    Veloce BioPharma LLC, Fort Lauderdale, Florida, United States
  • Samuel Barone MD
    Veloce BioPharma LLC, Fort Lauderdale, Florida, United States
  • Footnotes
    Commercial Relationships   Joseph Capriotti MD, Veloce BioPharma LLC (F), Veloce BioPharma LLC (I), Veloce BioPharma LLC (E), Veloce BioPharma LLC (P), Veloce BioPharma LLC (R); Jesse Pelletier MD FACS, Veloce BioPharma (I), Veloce BioPharma (P), Veloce BioPharma (C), Veloce BioPharma (F); Kara Capriotti, Veloce BioPharma (F), Veloce BioPharma (I), Veloce BioPharma (P), Veloce BioPharma (E); Samuel Barone MD, Veloce BioPharma (E), Veloce BioPharma (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3653. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joseph Capriotti MD, Jesse Pelletier MD FACS, Kara Capriotti, Samuel Barone MD; Efficacy of Topical Ophthalmic Agent VBP-100 Against Multi-Drug Resistant Biofilms of Staphylococcus aureus,Klebsiella pneumoniae, Pseudomonas aeruginosa and Candida albicans.
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):3653.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate novel topical antimicrobial VBP-100 against multi-drug resistant biofilm forming pathogens.

Methods : Biofilms of multi-drug resistant Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa and Candida albicans were developed on solid surfaces using the Calgary Biofilm Device (CBD) plate. Minimum biofilm eradication concentration (MBEC) was then determined for each test drug and for control samples of known antibiotics, ciprofloxacin and itraconazole

Results : VBP-100 completely eliminated all biofilms of bacterial and fungal species in the test systems. Ciprofloxacin was able to eradicate one bacterial biofilm only at concentrations greater than 0.25 ug/mL.

Conclusions : VBP-100 is a potent anti-bacterial and anti-fungal biofilm disrupting agent. Futher exploration in living systems is warranted.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×